MYC and B-cell non-Hodgkin lymphoma: To uncover drug vulnerabilities associated with BCR extinction in aggressive B cell lymphomas, we conditionally ablated surface BCR expression in the λ-MYC mouse B cell lymphoma model and screened 1475 small-molecule compounds, including clinically approved agents, on syngenic BCR-positive and BCR-negative tumor cells.